Generic Nexplanon Availability
NEXPLANON (etonogestrel - implant;implantation)
Manufacturer: ORGANON USA INC
Approval date: May 31, 2011
Strength(s): 68MG/IMPLANT [RLD]
Has a generic version of Nexplanon been approved?
No. There is currently no therapeutically equivalent version of Nexplanon available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nexplanon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
X-ray visible drug delivery device
Issued: May 13, 2014
Assignee(s): Meck Sharp & Dohme B.V.
The subject invention provides an X-ray visible drug delivery device for subdermal administration of a contraceptive or hormone replacement therapy.Patent expiration dates:
- September 28, 2027✓
- September 28, 2027
Applicator for inserting an implant
Issued: November 18, 2014
Assignee(s): Merck Sharp & Dohme B.V.
The invention pertains to an applicator (1) for inserting an implant, in particular a rod-like implant (2) containing an active substance, under the skin of a human or animal, comprising a housing (3), a cannula (6) extending from the housing (3), and a handle (15) for grasping and maneuvering the applicator (1) and the cannula (6) during insertion of an implant (2). In accordance with the invention, the handle (15) extends above at least part of the length of the cannula (6). Such a handle facilitates insertion of the cannula and/or accurate positioning of the implant.Patent expiration dates:
- August 28, 2026✓
- August 28, 2026
Applicator for inserting an implant
Issued: September 12, 2017
Assignee(s): MERCK SHARP & DOHME B.V.
The invention pertains to an applicator (1) for inserting an implant, in particular a rod-like implant (2) containing an active substance, under the skin of a human or animal, comprising a housing (3), a cannula (6), a cannula holder (9), an implant (2) accommodated inside the cannula (6) and/or the cannula holder (9), a protective cover (7) for the cannula (6), and a mechanism (22, 23, 7) which, at least after the cover (7) has been removed from the cannula (6), secures the implant (2) inside the cannula (6) and/or cannula holder (9). The mechanism (22, 23, 7) disengages the implant (2) during insertion of the cannula (6) or after the cannula (6) has been inserted. Substantially no lateral force will be exerted during the expelling of the implant from the cannula.Patent expiration dates:
- July 28, 2030✓✓
- July 28, 2030
More about Nexplanon (etonogestrel)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- En Español
- 3134 Reviews – Add your own review/rating
- Drug class: contraceptives
Other brands: Implanon
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|